Literature DB >> 1603639

Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.

R M Chanock1, R H Parrott, M Connors, P L Collins, B R Murphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1603639

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  14 in total

1.  Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

Authors:  A I Bot; T E Tarara; D J Smith; S R Bot; C M Woods; J G Weers
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

2.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

Authors:  G E Hancock; D J Speelman; K Heers; E Bortell; J Smith; C Cosco
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.

Authors:  Youngjoo Choi; Caleb S Mason; Les P Jones; Jackelyn Crabtree; Patricia A Jorquera; Ralph A Tripp
Journal:  Viral Immunol       Date:  2012-05-02       Impact factor: 2.257

5.  Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent.

Authors:  A Srikiatkhachorn; W Chang; T J Braciale
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.

Authors:  D Chargelegue; O E Obeid; S C Hsu; M D Shaw; A N Denbury; G Taylor; M W Steward
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse.

Authors:  R A Tripp; L Jones; L J Anderson
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

10.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.

Authors:  M Connors; A B Kulkarni; C Y Firestone; K L Holmes; H C Morse; A V Sotnikov; B R Murphy
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.